奥洛他定联合萘敏维治疗过敏性结膜炎疗效研究  

Clinical research on olopatadine and naphazoline hydrochloride in treatment of allergic conjunctivitis

作　　者：李淑敏[1] 薛秋萍[1] 

机构地区：[1]漯河市第三人民医院,河南漯河462000

出　　处：《医药论坛杂志》2012年第9期44-45,共2页Journal of Medical Forum

摘　　要：目的研究比较0.1%奥洛他定联合萘敏维滴眼液治疗过敏性结膜炎的疗效。方法 180例过敏性结膜炎患者随机分成观察组和对照组,对照组90例采用奥洛他定,观察组90例采用奥洛他定联合萘敏维,并于3d、7d、14d和停药1周后随访观察疗效。结果观察组眼痒眼红有效率明显高于对照组(P<0.05或0.01),无明显的不良反应。结论奥洛他定联合萘敏维治疗过敏性结膜炎效快、疗效好,且对组织几乎无不良反应,是治疗过敏性结膜炎的一种较理想药物。Objective To research the clinical effectiveness of 0. 1% Olopatadine and Naphazoline hydrochlorid on the patients with allergic conjunctivitis. Methods Totally 180 patients with allergic conjunctivitis were randonily di＇vided into two group,a control group （90 cases） and a observation group （90 cases）. The patients were used Olopatadin in control group while adding Naphazoline hydrochlorid in observation group. And they are observed 3 days and 7 days and 14 days after the treatment and one week after taking drug assessing clinical effectiveness of the two groups. Resets The responsive rates of the observation group were significantly higher than in the control group, and there were significances between two groups （P 〈 0. 05 or 0. 01 ）, there is no apparent side - effect in the treatment. Conclusions It can help improve the treatment efficiency and shorten the treatment time and has no serious adverse events.So it is an ideal drug in treatment of allergic conjunctivitis.

关 键 词：奥洛他定 萘敏维 过敏性结膜炎 

分 类 号：R777.31[医药卫生—眼科]